- Home
- FRBA vs RLMD Comparison
FRBA vs RLMD Comparison
Compare FRBA & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRBA | RLMD |
|---|---|---|
| Founded | 2007 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 377.6M | 307.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FRBA | RLMD |
|---|---|---|
| Price | $18.07 | $4.13 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $19.00 | $10.00 |
| AVG Volume (30 Days) | 66.5K | ★ 1.1M |
| Earning Date | 01-22-2026 | 11-13-2025 |
| Dividend Yield | ★ 1.35% | N/A |
| EPS Growth | ★ 3.13 | N/A |
| EPS | ★ 1.65 | N/A |
| Revenue | ★ $135,175,000.00 | N/A |
| Revenue This Year | $15.53 | N/A |
| Revenue Next Year | $5.97 | N/A |
| P/E Ratio | $10.79 | ★ N/A |
| Revenue Growth | ★ 9.51 | N/A |
| 52 Week Low | $12.74 | $0.24 |
| 52 Week High | $17.91 | $5.12 |
Technical Indicators
Market Signals| Indicator | FRBA | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 79.98 | 54.78 |
| Support Level | $15.93 | $3.98 |
| Resistance Level | $16.34 | $4.79 |
| Average True Range (ATR) | 0.38 | 0.46 |
| MACD | 0.23 | -0.08 |
| Stochastic Oscillator | 99.21 | 42.20 |
Price Performance
Historical ComparisonAbout FRBA First Bank
First Bank is a full-service commercial bank, with target businesses from individuals, businesses, and governmental entities located in service regions throughout New Jersey and eastern Pennsylvania, with a particular focus between New York City and Philadelphia. The group focuses on traditional deposit and loan products with businesses and individuals living and working in markets as the source of businesses. Its services are Business Banking; Personal banking; Digital Banking; and Lending.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.